• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Anti TB drug resistance in Tanga, Tanzania: a cross sectional facility base prevalence among pulmonary TB patients

    2015-10-31 02:18:28HaAbubakarHozaSayokiMfinangaBrigittenig

    Ha Abubakar S. Hoza, Sayoki G. M. Mfinanga, Brigitte K?nig

    1Department of Medical Microbiology & Epidemiology of Infectious Diseases, Medical Faculty, University of Leipzig, Germany

    2Department of Microbiology & Parasitology, Sokoine University of Agriculture, Morogoro, Tanzania

    3National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania

    Anti TB drug resistance in Tanga, Tanzania: a cross sectional facility base prevalence among pulmonary TB patients

    Ha Abubakar S. Hoza1,2*, Sayoki G. M. Mfinanga3, Brigitte K?nig1

    1Department of Medical Microbiology & Epidemiology of Infectious Diseases, Medical Faculty, University of Leipzig, Germany

    2Department of Microbiology & Parasitology, Sokoine University of Agriculture, Morogoro, Tanzania

    3National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania

    ARTICLE INFO

    Article history:

    in revised form 20 September 2015

    Accepted 15 October 2015

    Available online 20 November 2015

    Pulmonary tuberculosis

    Prevalence

    Drug resistance

    MDR TB

    HIV

    Facility base

    Objective: To determine the prevalence and risk factors associated with drug resistance tuberculosis (TB) at facility-base level in Tanga, Tanzania. Methods: A total of 79 Mycobacterium tuberculosis (MTB) isolates included in the study were collected from among 372 (312 new and 60 previously treated) TB suspects self referred to four TB clinics during a prospective study conducted from November 2012 to January 2013. Culture and drug susceptibility test of the isolates was performed at the institute of medical microbiology and epidemiology of infectious diseases, University hospital, Leipzig, Germany. Data on the patient's characteristics were obtained from structured questionnaire administered to the patients who gave informed verbal consent. Unadjusted bivariate logistic regression analysis was performed to assess the risk factors for drug resistant-TB. The significance level was determined at P<0.05. Results: The overall proportions of any drug resistance and MDRTB were 12.7% and 6.3% respectively. The prevalence of any drug resistance and MDRTB among new cases were 11.4% and 4.3% respectively, whereas among previously treated cases was 22.2% respectively. Previously treated patients were more likely to develop anti-TB drug resistance. There was no association between anti-TB drug resistances (including MDRTB) with the risk factors analysed. Conclusions: High proportions of anti TB drug resistance among new and previously treated cases observed in this study suggest that, additional efforts still need to be done in identifying individual cases at facility base level for improved TB control programmes and drug resistance survey should continuously be monitored in the country.

    Document heading doi:10.1016/j.apjtm.2015.10.014

    1. Introduction

    Tuberculosis (TB) continues to be a major health challenge globally despite the efforts to combat the disease. Increased drug resistant strains in many parts of the world has worsen the situation[1]. Escalating human immunodeficiency virus (HIV)infection, increased prevalence of nontuberculous mycobacteria(NTM), poverty, and inadequacy public health infrastructure havealso contributed greatly in worsening the situation[2].

    During the last two decades, the World Health Organization and the International Union Against Tuberculosis and Lung Disease set up a global project to monitor the development of drug-resistant tuberculosis (DR-TB). Since that time approximately 60% of all countries in the world have implemented surveillance activities[3].

    HIV epidemic and the emergence of drug resistant TB threaten the efforts to reduce the global burden of TB by 2015 that aims at ensuring that all TB patients benefit from universal access to high quality diagnosis and patient centred treatment[4]. Treatment of multi drug resistant-TB (MDR-TB) is undoubtedly costly and requires longer treatment with more toxic drugs compared to drug susceptible TB[5,6]. Incorrect drug regimes, non adherenceto treatment, transmission in congregate settings, substandard drug quality, as well as erratic drug supply are key risk factors for drug resistance development[7,8]. Several studies have reported unacceptably high mortality rates among HIV infected patients with MDR-TB[9,10].

    Principally, drug resistance data are obtained through continuous surveillance by routine testing of all TB patients. However, in resource-poor settings like Tanzania, periodic drug resistance surveys (DRS) based on random, representative drug susceptibility testing (DST) among previously untreated smear-positive cases are seldom performed. Laboratories performing culture and DST are scarce and very often overburdened with divergent tasks for the TB control programme. Consequently, only phenotypic DST has been customarily performed; frequently faced with notable logistics and operational challenges[11], and therefore impeding regular DRS and precise surveillance. Generally, DST of Mycobacterium tuberculosis (M. tuberculosis) (MTB) demands the presence of biosafety laboratories, which are rarely found outside reference centres in many resource-poor settings. Moreover, rapid transport of sputum from remote areas of the country to the reference laboratory is required to minimize losses due to contamination or growth failure. Poor infrastructure and unsustainable logistics in these settings humper this.

    Tanzania is among the 22 high TB burden countries, with an estimated incidence (all forms) in 2007 and 2012 of 297 and 295 per 100 000 population respectively[12,13]. Available data on the prevalence of DR-TB and MDR-TB in Tanzania are still low owing to improved case management. Although the levels of anti-TB drug resistance in the country are still low, the need for continuous monitoring has always been emphasized[11,14]. The most effective strategies for limiting further spread of drug-resistant TB include rapid detection of drug resistance followed by prompt and effective therapy of each case. Routine surveillance linked to patient care,represents the best approach to monitor drug resistance[3].

    Limited anti-TB drug resistance surveys have been conducted in Tanzania, the last one being in 2007 as part of national representative sample of TB patients[11]. Since that time, no survey has been conducted outside the national survey. The present study aimed at assessing the magnitude of anti TB drug resistance and associated risks among newly, and previously treated pulmonary TB patients at facility-base level in Tanga, Tanzania.

    2. Materials and methods

    2.1. Study design, area and study population

    A total of 79 M. tuberculosis isolates collected from among 372 new and previously treated TB patients during a prospective study conducted in Tanga, Tanzania from November 2012 to January 2013 were eligible for this study. All patients with clinical signs and symptoms suggestive of TB self-referred to four TB clinics were eligible for the study. The clinics included Makorora and Ngamiani health centres, Bombo Regional referral hospital and Muheza designated District hospital. Demographic information and data were collected only after provision of informed consent. A careful cross examination of patient history for previous anti-TB treatment using a structured questionnaire was used to classify patients as‘new' or ‘repeat' TB cases. A patient was considered as 'new case' if had not received anti-TB treatment for a period >1 month and was considered ‘repeat' if had received anti TB drugs in a period less or equal to 1 month. No restrictions on inclusion criteria regarding clinical symptoms and age of the patients.

    2.2. Sputum and data collection

    Demographic data was obtained by using structured questionnaire administered to the patients attending four TB clinics who provided informed verbal consent to the study. Two sputum samples (one spot during the initial visit to the clinic and one early morning)were collected into small autoclavable wide mouth glass bottles. The specimens were examined by direct smear microscopy at the respective clinics using either Ziehl Neelsen stain (Makorora and Ngamian health centres) or fluorescence stain (Bombo referral hospital and MDHH). Diagnosis of smear-positive TB was performed based on the national tuberculosis and leprosy programme guidelines[15]. All morning sputum samples were kept at -20 ℃ at the respective clinics. No preservative was added until shipped to the Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University hospital, Leipzig, Germany for culture and molecular analysis. HIV status of the patients was determined by rapid HIV screening method at the treatment and care centres of the respective clinics.

    2.3. Sputum culture and identification of mycobacterial isolates

    Sputum specimens were digested and decontaminated using N-acetyl-L-cysteine-sodium hydroxide method[16] and were reexamined for the presence of acid-fast bacilli by fluorescence stain in Leipzig. The isolates were cultured in BacT/Alert? 3D liquid culture system (bioMe′rieux) and on L?weinstein- Jensen and Gottsacker slants (Artelt-ENCLIT GmbH, Wyhra, Germany). Gottsacker slopes contains sodium pyruvate for isolation of Mycobacterium bovis. Cultures were incubated at 37 ℃ for up to 8 weeks. Confirmation of MTB was done based on presumptive phenotypic appearance of colonies and by line probe assay (GenoType?MTBC; Hain Lifescience, Nehren, Germany).

    2.4. Phenotypic drug susceptibility testing by BacT/Alert? 3D system

    M. tuberculosis isolates were tested for their resistance to rifampicin(RMP), isoniazid (INH), streptomycin (SM), ethambutol (EMB) and pyrazinamide (PZA) by a proportion method using BacT/Alert? 3D system. Critical concentrations of 1 μg/mL for RMP, INH, and SM; 2 μg/mL for EMB and 200 μg/mL for PZA were respectively used[17,18]. The PZA bottles were incubated in BacT/Alert? 3Dautomated system at 37 ℃, as mycobacteria designed blood culture bottles to inactivate the delta algorithm of the system for growth detection in order to avoid false drug resistant results. Growth was monitored daily, and an isolate was considered resistant to a drug under test when the drug-containing bottle had a time to detection(TTD) that was less or equal to the TTD of the 1% control bottle.

    Definitions: Any resistance was defined as resistance to one or more first line anti TB drugs. Mono-resistance was defined as resistance to only one of the first line anti-TB drugs (INH, RMP, SM, EMB and PZA). MDR-TB was defined as M. tuberculosis isolate that is resistant to at least INH and RMP. Resistance among new cases was defined as patient with TB resistant to one or more anti TB drugs,but who had never been previously treated for TB. Resistance among previously treated cases, was defined as patients diagnosed with TB who started anti-TB treatment and subsequently acquired resistance to one or more of the drugs used during treatment[19].

    2.5. M. tuberculosis genomic DNA extraction

    Mycobacterial cells from positive BacT/Alertt? bottles and from LJ slopes showing visible positive growth were used for DNA extraction. Briefly, bacterial DNA was extracted from heatinactivated AFB isolates. A loopful of colony material was placed into a labelled screw caped eppendorf tube containing 500 μL sterile distilled water or by taking 500 μL from a positive BacT/Alert? bottles. Each specimen was incubated on a heat block at 95 ℃ for 20 min to inactivate the bacteria. Then centrifuged at 14 000 g for 15 min, the supernatant was discarded using pasture pipette, followed by addition of 200 μL distilled water to resuspend the pellets. This was followed by maximum vortexing for 10 s to homogenize the sediments. The tubes were incubated in an ultrasonic water bath at 95 ℃ for 15 min in order to rupture the inactivated mycobacterial cells to release the genomic DNA. The tubes were finally centrifuged at 14 000 g for 15 min. The supernatant was immediately used for PCR or transferred to a new sterile eppendorf for longer storage at -20 ℃ until used.

    2.6. Genotypic drug susceptibility testing

    Genotypic drug susceptibility testing for RMP and INH was performed using Genotype?MTBDRplus assay (Hain Life Science GmbH, Nehren, Germany). Genotypic detection of resistance to EMB was done by using Genotype?MTBDRsl assay (Hain Life Science GmbH, Nehren, Germany). PCR amplification, strip hybridization and interpretation of profiles were done by following manufacturer's instructions.

    2.7. Data management and analysis

    Data were first entered and cleared by using Ms Excel, then analysed using SPSS version 20 (SPSS Inc, Chicago, IL, USA). Unadjusted bivariate logistic regression analysis was performed to determine the risk factors for drug-resistant TB and the strength of the association was determined by odds ratio (OR) with 95% confidence interval (95% CI) and P value of < 0.05 was considered statistically significant.

    The study was approved by the Ethical Review Committee of the National Institute for Medical Research, Dar es salaama, Tanzania. All patients gave verbal informed consent to participate in the study.

    3. Results

    3.1. M. tuberculosis culture results

    From among 372 TB suspect patients enrolled in the study 312(83.9%) were new and 60 (16.1%) were previously treated cases. Of the 312 new cases enrolled, 182 (58.3%) were culture negative,33 (10.6%) contaminated and 97 (31.1%) had culture positive results. Of the 97 cases with culture positive results, 27 (27.8%)were excluded from the study because they were NTMs; only 70(72.2%) cases from this category were eligible for DST. Of the 60 previously treated cases, 42 (70%) were culture negative, 5 (8.3%)were contaminated and 13 (21.7%) were culture positive. Four(30.8%) cases were excluded from the test because they were NTMs and nine (69.2%) were eligible for the DST. Overall, 79 (21.2%) out of 372 patients with positive M. tuberculosis isolates were eligible for phenotypic and genotypic DST as illustrated in Figure 1.

    3.2. Demographic characteristics of the patients

    The demographic characteristics of 79 (21.2%) patients who had positive MTB isolates were analysed for DST of the first line anti-TB drugs in this study. 70 (88.6%) were new and 9 (11.6%) were previously treated (repeat) cases. These included 55 (69.6%) males and 24 (30.4%) females with the mean age of (35.8±12.6) years. Other demographic characteristics of the patients are shown in Table 1.

    Table 1 Characteristics of patients enrolled for anti-TB drug susceptibility test in Tanga, Tanzania, November 2012-January 2013.

    3.3. Drug resistance prevalence by phenotypic DST

    Of the 79 patients with DST data, the overall proportion of any drug resistance was 12.7% (n = 10/79) and that of MDR-TB was 6.3% (n = 5/79). The proportion of any drug resistant anti TB drug among new cases was 11.4% (n = 8/70) and the proportion of MDR-TB in this category was 4.3% (n = 3/70); whereas resistance to any drug and that of MDR-TB among previously treated cases were respectively 22.2% (n = 2/9). The proportions of any drug resistance and MDR-TB among HIV sero positive patients were 30.8% (n = 4/13) and 23.1% (n = 3/13) respectively, while among the sero negative group were 9.1% (n = 6/66) and 3.0% (n = 2/66)respectively (Table 2).

    3.4. Analysis of risk factors associated with any drug resistance and MDR-TB

    Using unadjusted logistic regression model risk factors associated with any drug resistance and MDR-TB were determined. The patients were grouped into seven groups with the following characteristics in each group: Sex: males 55 (69.6%) cases, females 24 (30.4%) cases; age <35years: 41 (51.9%) cases; age≥35 years:38 (48.1%). With respect to residence, 40 (50.6%) were from urban and 39 (49.4%) from rural. Seventy (88.6%) were new and 9(11.4%) were previously treated cases. With respect to HIV status 13 (16.5%) were HIV sero-positive, and 66 (83.5%) were seronegative. With respect to disease type 55 (69.4%) were both smear and culture-positive, while 24 (30.4%) were smear-negative but culture-positive. Regarding disease type, we interestingly detected 8.0% (n = 2/25) cases with any drug resistance and 4.0% (n =1/25)case of MDR-TB among smear negative but culture positive patients. There was no significance difference among all variables analysed with development of any drug resistance or with MDR-TB in this population as shown in Table 2.

    3.5. Resistance patterns of M. tuberculosis isolates

    Table 3 shows different resistance patterns among new and previously treated (repeat) cases. Overall 87.3% of all cases were susceptible to all first line anti-TB drugs. Among the newly registered patients, any resistance to INH and RMP was each found in four (5.7%) isolates, resistance to SM in three (4.3%), any resistance to EMB and PZA was each found in 2 (2.9%) isolates and 4 (5.7%) isolates showed MDR-TB. Among the previously treated cases, any resistance to INH, SM and EMB were each foundin 2 (22.2%) cases, any resistance to RMP and PZA was each found in one (11.1%) case and MDR-TB was found in one (11.1%)case, which was resistant to all first line ant TB drugs. The overall prevalence of any resistance and MDR-TB when new and previously treated cases were combined was 12.7% and 6.3% respectively. Mono-resistance was only observed for SM and PZA in 1.4% each,all being from newly registered cases as shown in Table 3.

    Table 2 Unadjusted bivariate logistic regression analysis of risk factors associated with any drug resistance and MDR-TB.

    Table 3 Drug resistance patterns to first line anti TB drugs in Tanga, Tanzania (new vs repeat cases).

    3.6. Comparison between phenotypic and genotypic drug susceptibility testing

    Congruent results between phenotypic DST performed by BacT/ Alert? 3D system and Genotype?MTBDRplus assay were obtained in 72 (91.1%) of the 79 subjects. Of 72 isolates identified as being susceptible to both INH and RMP by BacT/Alert? 3D, 66 (91.7%)cases were congruent by Genotype?MTBDRplus. 3 (4.2%) isolates were detected as MDR-TB by both methods and all with mutations in the rpoβ gene and katG gene as shown by Genotype?MTBDRplus. Two (40.0%) isolates detected by BacT/Alert? 3D as MDRTB, were detected by the Genotype?MTBDRplus assay as being RMP mono-resistant. Overall Genotype?MTBDRplus detected 3(3.8%) isolates as RMP mono-resistant, whereas no isolate could be detected as RMP mono-resistant by the BacT/Alert? 3D. On the other hand, 2 (2.5%) isolates were detected by either methods as INH mono-resistant; with one (1.4%) having mutation in katG gene and one missed by the genotypic method as depicted in Table 4.

    4. Discussion

    Our key findings show that the prevalence of resistance to any anti-TB drug among new patients was 11.4% and that of MDR-TB was 4.3%, whereas among previously treated patients the resistance to any anti-TB drug and MDR-TB were respectively 22.2%. The overall resistance to any anti-TB drugs and MDR-TB when newly and previously treated cases were combined was 12.7% and 6.3% respectively. The overall prevalence to any resistance of 7.6% for INH; 6.3% for RMP and SM; 5.1% for EMB and 3.8% for PZA were high. The levels reported in our study are higher than those reported during the last national DST survey[11]. These proportions are alarming, hence calling for immediate intervention to reverse the trend, as it raises concern on the increased transmission of drug resistant MTB in the settings.

    High proportion of resistance to any drug (22.2%) and MDR-TB among previously treated patients, also rises concerns on continual reliance on home-based supervision of TB treatment as previously advocated[20]; as patient adherence to treatment may be difficult to monitor, since the supervision of patients at home is made by nonmedical professionals. Moreover, the existence of other resistance patterns with INH and or RMP among previously treated patientsfurther reaffirms the concern over the home-based supervision of TB patients. Although no association to any anti-TB drug and or MDRTB was found between newly and previously treated cases, our findings show that 22.2% (n = 2/9) of the previously treated cases were more likely to develop resistance to first line anti-TB drugs. Lack of association between history of treatment with DR-TB and MDR-TB observed could be due to low number of previously treated patients enrolled during the study.

    Table 4 Comparison of resistance patterns of 79 M. tuberculosis isolates to INH and RMP by phenotypic and genotypic method.

    Observed mono resistance to SM and PZA in 2.9 % among new patients is plausibly an indication of growing use of these antibiotics in the treatment of other bacterial infections in the community. Generally, our findings are well in agreement with those of the nation-wide survey, which showed the prevalence of any resistance among new and previously treated patients in the range of 8.3% and 20% respectively[11]. The observed resistance to PZA in this study is, to the best of our understanding reported for the first time in Tanzania. The standard practice for drug resistance surveys has been to test for four first line drugs (INH, RMP, EMB and SM); and for the purposes of surveys NTPs are required to perform, at minimum DST for INH and RMP on all cases included in the survey[21]. From the findings of this study, it may be worth including DST for PZA especially among HIV positive patients.

    The findings of any drug resistance of 8.0% and of MDR-TB 4.0% among smear-negative but culture-positive patients in this study need to be addressed with special concern, as this suggests the inadequacy of peripheral microscopy performance. Several studies have shown that peripheral smear microscopy in Tanzania has frequently more problems in false-negative slides than in false-positive[22].

    Although several reports from other countries, have documented that HIV positivity is an important risk factor associated with primary MDR-TB[23-26], and that HIV infection has been associated with MDR-TB outbreaks in institutional settings, such as hospitals and prisons[27,28]. Our findings showed lack of association between anti-TB drug resistance in patients with or without HIV and these results are in agreement with studies conducted in Mwanza,Tanzania[14]. This lack of association could be explained by the fact that majority of HIV infected TB patients are likely to be smear negative and tend to have lower rate of sputum smear positivity[29]. Of the 5 (6.3%) MDR isolates detected in our study, 2/5 isolates showed discordant results by BacT/Alert? 3D system and Genotype?MTBDRplus. While BacT/Alert? 3D detected all isolates as being INH resistant, the later detected one of the isolate as INH mono-resistant and the other as INH susceptible. Possible explanation of this disparity could be due to presence of mutations outside the 81-bp “hot-spot” of the rpoB gene, though this does occur less frequently[30,31]. Such mutations may occur for example at codon 490 CAG to CAG[32], codon 534 (GGG to GAG),codon 535 (CCC to CAC)[33] and at codon 572 (ATC to TTC)[34]. Another possible explanation could be due to changes occurring in genes whose products participate in antibiotic permeation or metabolism[35]. Several studies have also indicated presence of high discordance in RMP susceptibility testing[36,37]. Since the Genotype?MTBDRplus assy we used is not very robust; such methods like DNA sequencing may be considered for isolates with discordant results.

    Limitations: The small sample size may have limited the generalization of the observed results in our study. High rates of culture negative and contaminated specimens may be attributed to such factors as: (i) inclusion of specimens with very low bacilli load resulting to loss of viability during culture, (ii) understaffed and overburdened of the clinics with other non-TB patients might have led to delayed sample processing, (iii) frequent power interruption may have resulted into inappropriate cold chain maintenance at the clinic level, (iv) some patients failing to deliver early morning samples within the specified period, due to among other factors long distance and costs of travel to and from the clinics. Despite the limitations of the study, it has provided important information regarding the resistance profiles at the facility-base level where majority of the patients may not have opportunity to be covered during the national drug resistance surveys. High proportions of anti-TB drug resistance among new and previously treated cases,gives an insight of DR-TB situation at facility levels in the country. Therefore, it provides for a better planning of the drug resistance surveys including improving smear microscopy performance for case detection and improvement of TB control programmes. Frequent drug resistance survey need to be done in order to monitor the situation of DR-TB in the country.

    Conflict of interest statement

    We declare that we have no conflict of interest.

    Acknowledgements

    We are grateful to the management and technical personnel of the TB clinics and TB coordinators in Muheza and Tanga. We thank Ms. Elizabeth Kraftschek and Dr. Joerg Beer of the Department of Medical Microbiology and Epidemiology of Infectious Diseases,University Hospital Leipzig for their technical support throughout the study. We acknowledge the financial support from the Germany Academic Exchange Service (DAAD).

    [1] WHO. Molecular line probe assay for screening of patients at high risks of multidrug-resistant tuberculosis (MDR-TB): Policy statement. Geneva:WHO; 2008.

    [2] Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosiscontrol programs, Am Rev Respir Dis 1991; 144(4): 745-749.

    [3] Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M, Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis 2011; 52: 901—906.

    [4] Corbet EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC,et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009—1021.

    [5] Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 2013; 8: e54587.

    [6] Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63—80.

    [7] Lambregts-van Wezenbeek CSB, Veen J. Control of drug-resistant tuberculosis. Tubercle Lung Dis 1995; 76:455-459.

    [8] WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update. Geneva: WHO; 2008.

    [9] Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196(Suppl 1): S86-S107.

    [10] Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 2009. DOI:10.1371/journal.pone.0007186

    [11] Chonde TM, Basra D, Mfi nanga SGM, Range N, Lwilla L, Shirima RP,et al. National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis 2010; 14: 967—972.

    [12] WHO. Global tuberculosis control: Surveillance, planning, financing. Geneva: WHO; 2014.

    [13] MOHSW. The first national tuberculosis prevalence survey in the United Republic of Tanzania: Primary analysis. Geneva: WHO; 2012.

    [14] Range N, Friis H, Mfaume S, Magnussen P, Changalucha J, Kilale A, et al. Anti-tuberculosis drug resistance pattern among pulmonary tuberculosis patients with or without HIV infection in Mwanza, Tanzania. Tanzania J Health Res 2012; 14: 1—9.

    [15] NTLP. Manual of the national tuberculosis and leprosy programme in Tanzania. Tanzania: Minister for Health and Social Welfare; 2006.

    [16] Kent PT, Kubica GP. Public health mycobacteriology: a guide for the levelⅢ laboratory. Atlanta: Dept. of Health and Human Services, Public Health Service, Centers for Disease Control; 1985.

    [17] Beer J, Küchler R, Rodloff AC. Investigations about the possibility for testing the susceptibility of mycobacteria with the MB/BacT culture system. Laboratoriums Medizin 1997; 21: 390—401.

    [18] Tortoli E, Mattei R, Savarino A, Bartolini L, Beer J. Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika)systems. Diagn Microbiol Infect Dis 2000; 38: 83—86.

    [19] WHO. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. Geneva, Switzerland: WHO; 2009.

    [20] Egwaga S, Range N, Lwilla F, Mkopi A, Barongo V, Mtenga S, et al. Assessment of patient preference and observation of anti-tuberculosis medication in three districts in Tanzania. Tanzania: Dove Medical Press Ltd; 2008, p. 1—6.

    [21] WHO. Interim recommendations for the surveillance of drug resistance in tuberculosis. Geneva: WHO; 2007.

    [22] Mfinanga G, Ngadaya E, Mtandu R, Mutayoba B, Basra D, Kimaro G,et al. The quality of sputum smear microscopy diagnosis of pulmonary tuberculosis in Dar es Salaam, Tanzania. Tanzania Health Res Bull 2007;9: 164—168.

    [23] Yoshiyama T, Supawitkul S, Kunyanone N, Riengthong D, Yanai H, Abe C, et al. Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand. Int J Tuberc Lung Dis 2001; 5: 32—39.

    [24] Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158—163.

    [25] Quy HT, Cobelens FGJ, Lan NTN, Buu TN, Lambregts CSB, Borgdorff MW. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 45—51.

    [26] WHO. Molecular line probe assays for rapid screening of patients at risk of multi-drugresistant tuberculosis (MDR-TB): Expert group report. Geneva Switzerland: WHO; 2008.

    [27] Pfyffer GE, Str?ssle A, van Gorkum T, Portaels F, Rigouts L, Mathieu C, et al. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerging Infect Dis 2001; 7: 855—861.

    [28] Steenland K, Levine J, Sieber K, Schulte P, Aziz D. Incidence of tuberculosis infection among New York prison employees. Am J Public Health 1997; 87: 2012—2014.

    [29] Burman W, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Resp Infect 2003: 18; 263—271.

    [30] Minh NN, van Bac N, Son NT, Lien VT, Ha CH, Cuong NH, et al. Molecular characteristics of rifampin- and isoniazid-resistant mycobacterium tuberculosis strains isolated in Vietnam. J Clin Microbiol 2012; 50: 598—601.

    [31] Ranganath R, Kumar GSV, Javali V, Ranganath R. Line probe assay as a rapid tool for detection of MDRTB. Ann Res Rev Biol 2014; 4: 246—257.

    [32] Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40: 4435—4438.

    [33] Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB Gene of Multidrug-Resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol 2001; 39: 2987—2990.

    [34] Aktas E, Durmaz R, Yang D, Yang Z. Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey.[Online]. Available from http://online. liebertpub.com/doi/abs/10.1089/mdr.2005.11.94 [Accessed on October 3,2014].

    [35] Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN,et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampicinresistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32: 1095—1098.

    [36] van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM,et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501—3506.

    [37] Kalokhe AS, Shafiq M, Lee JC, Metchock B, Posey JE, Ray SM, et al. Discordance in Mycobacterium tuberculosis rifampin susceptibility. Emerging Infect Dis 2012; 18: 537—539.

    15 August 2015

    Abubakar S. Hoza, Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital, Liebigstrasse 21, Leipzig,Germany.

    Tel: 491777921431

    Fax: +493419715209

    E-mail: abshoza@gmail.com

    欧美日韩av久久| 自拍欧美九色日韩亚洲蝌蚪91| 黄片播放在线免费| 亚洲精品国产区一区二| 亚洲视频免费观看视频| 成年人黄色毛片网站| 欧美国产精品一级二级三级| 一二三四在线观看免费中文在| 国产一区有黄有色的免费视频| 国产精品自产拍在线观看55亚洲 | 午夜成年电影在线免费观看| 国产精品1区2区在线观看. | 国产免费现黄频在线看| 99久久国产精品久久久| 女人爽到高潮嗷嗷叫在线视频| 好男人电影高清在线观看| 亚洲熟妇熟女久久| 日韩有码中文字幕| 男男h啪啪无遮挡| 纯流量卡能插随身wifi吗| 高清视频免费观看一区二区| 69精品国产乱码久久久| 精品卡一卡二卡四卡免费| 亚洲全国av大片| 在线天堂中文资源库| 国产av又大| 最新美女视频免费是黄的| 国产精品免费视频内射| 欧美黄色片欧美黄色片| av福利片在线| 搡老熟女国产l中国老女人| 国产精品影院久久| 露出奶头的视频| 欧美日韩福利视频一区二区| 色播在线永久视频| 丁香欧美五月| 夜夜爽天天搞| 国产精品一区二区在线不卡| 亚洲精品国产区一区二| 91成年电影在线观看| 日韩有码中文字幕| 一本综合久久免费| av欧美777| 精品福利永久在线观看| 久久影院123| 亚洲欧美激情在线| 国产在线免费精品| 一本—道久久a久久精品蜜桃钙片| 黑人操中国人逼视频| 精品亚洲乱码少妇综合久久| 51午夜福利影视在线观看| 国产区一区二久久| 97人妻天天添夜夜摸| 国产真人三级小视频在线观看| 亚洲精品中文字幕一二三四区 | 高清视频免费观看一区二区| 日韩有码中文字幕| 色播在线永久视频| 亚洲欧美色中文字幕在线| 肉色欧美久久久久久久蜜桃| 熟女少妇亚洲综合色aaa.| 一边摸一边抽搐一进一出视频| 亚洲精品国产区一区二| 天天添夜夜摸| 国产激情久久老熟女| 国产精品99久久99久久久不卡| h视频一区二区三区| 亚洲黑人精品在线| 伦理电影免费视频| 欧美日韩亚洲高清精品| 成年人免费黄色播放视频| 久久久国产成人免费| 亚洲精品av麻豆狂野| 999久久久国产精品视频| 性高湖久久久久久久久免费观看| 亚洲伊人久久精品综合| 欧美日韩av久久| 少妇被粗大的猛进出69影院| 国产熟女午夜一区二区三区| 日韩免费高清中文字幕av| 欧美av亚洲av综合av国产av| 亚洲av国产av综合av卡| 日日摸夜夜添夜夜添小说| 男人舔女人的私密视频| 狠狠狠狠99中文字幕| 国产精品久久电影中文字幕 | 伊人久久大香线蕉亚洲五| 成人免费观看视频高清| 久久久久视频综合| 黄网站色视频无遮挡免费观看| 精品乱码久久久久久99久播| 精品国产一区二区久久| 一边摸一边抽搐一进一出视频| 亚洲中文字幕日韩| 国产无遮挡羞羞视频在线观看| 久久久久久人人人人人| 欧美精品高潮呻吟av久久| 亚洲久久久国产精品| 亚洲一卡2卡3卡4卡5卡精品中文| 精品国产国语对白av| 天天躁狠狠躁夜夜躁狠狠躁| 麻豆av在线久日| av天堂久久9| 亚洲精品国产区一区二| 亚洲九九香蕉| 丰满人妻熟妇乱又伦精品不卡| 岛国在线观看网站| 国产精品影院久久| 国产视频一区二区在线看| 亚洲一卡2卡3卡4卡5卡精品中文| 高清毛片免费观看视频网站 | 亚洲精品国产一区二区精华液| 欧美国产精品一级二级三级| 大片免费播放器 马上看| 亚洲欧美精品综合一区二区三区| 美女视频免费永久观看网站| 丁香欧美五月| 亚洲精品粉嫩美女一区| 又大又爽又粗| 桃花免费在线播放| 国产成人av激情在线播放| www日本在线高清视频| 在线亚洲精品国产二区图片欧美| 亚洲国产看品久久| 亚洲五月婷婷丁香| 日韩免费高清中文字幕av| 亚洲国产看品久久| 亚洲人成电影免费在线| 成年人午夜在线观看视频| 考比视频在线观看| 久久久精品国产亚洲av高清涩受| 激情在线观看视频在线高清 | 成年人黄色毛片网站| 丁香六月欧美| avwww免费| 桃红色精品国产亚洲av| 日韩免费高清中文字幕av| 久热这里只有精品99| tocl精华| 欧美性长视频在线观看| 十八禁网站免费在线| 精品一区二区三区四区五区乱码| 亚洲精品一卡2卡三卡4卡5卡| 亚洲成av片中文字幕在线观看| 精品国产一区二区久久| 黑人巨大精品欧美一区二区mp4| 中文字幕人妻丝袜一区二区| 首页视频小说图片口味搜索| 中文亚洲av片在线观看爽 | 国产精品成人在线| 高清在线国产一区| 久久久久久亚洲精品国产蜜桃av| www.精华液| 亚洲自偷自拍图片 自拍| 亚洲色图av天堂| 亚洲 国产 在线| 久久中文字幕一级| 人人妻人人添人人爽欧美一区卜| 天天影视国产精品| 久久香蕉激情| 亚洲精品一卡2卡三卡4卡5卡| 国产欧美日韩精品亚洲av| 精品久久久久久电影网| 黑人巨大精品欧美一区二区mp4| 国产一区二区激情短视频| 日韩中文字幕视频在线看片| 亚洲精品中文字幕在线视频| 久久99一区二区三区| 91老司机精品| 日本欧美视频一区| 精品国产乱码久久久久久小说| 高清欧美精品videossex| 国产精品国产av在线观看| 最黄视频免费看| av不卡在线播放| 亚洲,欧美精品.| 国产极品粉嫩免费观看在线| 国产精品亚洲一级av第二区| 男女之事视频高清在线观看| 国产99久久九九免费精品| 丁香欧美五月| 无人区码免费观看不卡 | 亚洲色图 男人天堂 中文字幕| 激情在线观看视频在线高清 | 久9热在线精品视频| 99久久99久久久精品蜜桃| 国产又色又爽无遮挡免费看| 亚洲一卡2卡3卡4卡5卡精品中文| 九色亚洲精品在线播放| 国产精品av久久久久免费| 国产片内射在线| 大型黄色视频在线免费观看| 亚洲人成电影观看| 香蕉久久夜色| 久久国产精品男人的天堂亚洲| 国产亚洲精品久久久久5区| 亚洲精品中文字幕一二三四区 | 亚洲伊人色综图| 亚洲精品国产精品久久久不卡| 一级片免费观看大全| 日韩中文字幕视频在线看片| 美女福利国产在线| 老司机靠b影院| 深夜精品福利| 亚洲人成电影观看| 亚洲精品国产色婷婷电影| 亚洲一区中文字幕在线| 丝袜喷水一区| 亚洲九九香蕉| 国产97色在线日韩免费| 国产成+人综合+亚洲专区| 久久精品国产a三级三级三级| 露出奶头的视频| 一进一出抽搐动态| 老司机在亚洲福利影院| 99精国产麻豆久久婷婷| xxxhd国产人妻xxx| av视频免费观看在线观看| 亚洲国产av影院在线观看| av免费在线观看网站| 日韩熟女老妇一区二区性免费视频| 午夜久久久在线观看| 亚洲国产成人一精品久久久| 十八禁人妻一区二区| av电影中文网址| 欧美黑人欧美精品刺激| 久久久精品94久久精品| 黑人巨大精品欧美一区二区蜜桃| 欧美日韩视频精品一区| 在线观看免费视频日本深夜| 天天操日日干夜夜撸| 91精品国产国语对白视频| 国产av一区二区精品久久| 日本vs欧美在线观看视频| 亚洲成人免费电影在线观看| 电影成人av| 亚洲av片天天在线观看| 国产一区二区三区综合在线观看| 国产高清国产精品国产三级| 亚洲国产看品久久| 首页视频小说图片口味搜索| 日韩欧美国产一区二区入口| 亚洲人成电影观看| 曰老女人黄片| 人人妻人人爽人人添夜夜欢视频| 美女主播在线视频| 2018国产大陆天天弄谢| 日韩免费高清中文字幕av| 国产高清激情床上av| 亚洲精华国产精华精| 人妻久久中文字幕网| 国产精品久久久久成人av| tube8黄色片| 精品免费久久久久久久清纯 | 多毛熟女@视频| 妹子高潮喷水视频| 亚洲久久久国产精品| 波多野结衣一区麻豆| 男男h啪啪无遮挡| tube8黄色片| 欧美在线一区亚洲| 免费久久久久久久精品成人欧美视频| 亚洲欧美日韩另类电影网站| 美女高潮喷水抽搐中文字幕| 精品一区二区三区四区五区乱码| 不卡av一区二区三区| 欧美变态另类bdsm刘玥| 99香蕉大伊视频| 成人精品一区二区免费| 成年人免费黄色播放视频| 免费av中文字幕在线| 免费看a级黄色片| 波多野结衣一区麻豆| 国产精品1区2区在线观看. | 一区在线观看完整版| 九色亚洲精品在线播放| 51午夜福利影视在线观看| 一区二区三区国产精品乱码| 国产在线免费精品| 99精品在免费线老司机午夜| 老汉色av国产亚洲站长工具| 久久热在线av| 热99久久久久精品小说推荐| 国产精品欧美亚洲77777| 丝袜喷水一区| 日韩大片免费观看网站| 精品亚洲成a人片在线观看| 最黄视频免费看| 日韩中文字幕欧美一区二区| 日韩大码丰满熟妇| 精品少妇一区二区三区视频日本电影| 最近最新免费中文字幕在线| 精品福利观看| 天天操日日干夜夜撸| 国产成+人综合+亚洲专区| 女性生殖器流出的白浆| 亚洲综合色网址| 老汉色∧v一级毛片| 亚洲精品一二三| 18在线观看网站| 亚洲中文日韩欧美视频| 日本五十路高清| 成在线人永久免费视频| 国产极品粉嫩免费观看在线| 亚洲成人手机| 精品视频人人做人人爽| 在线观看免费日韩欧美大片| 亚洲色图综合在线观看| 免费黄频网站在线观看国产| 一夜夜www| 国产高清videossex| 国产成人欧美| 国产精品av久久久久免费| av又黄又爽大尺度在线免费看| 国产亚洲av高清不卡| 亚洲久久久国产精品| 十分钟在线观看高清视频www| 777久久人妻少妇嫩草av网站| 国产免费现黄频在线看| 亚洲中文日韩欧美视频| 久久久国产精品麻豆| 我的亚洲天堂| 久久久久精品人妻al黑| 久久人人爽av亚洲精品天堂| 一本一本久久a久久精品综合妖精| √禁漫天堂资源中文www| 波多野结衣av一区二区av| 亚洲国产av影院在线观看| 国产欧美日韩一区二区三区在线| 国产精品美女特级片免费视频播放器 | 蜜桃在线观看..| 熟女少妇亚洲综合色aaa.| 国产精品久久久av美女十八| 色综合欧美亚洲国产小说| tube8黄色片| 最新在线观看一区二区三区| 国产亚洲精品第一综合不卡| 国产单亲对白刺激| 搡老岳熟女国产| 18禁黄网站禁片午夜丰满| 每晚都被弄得嗷嗷叫到高潮| 国产精品美女特级片免费视频播放器 | 亚洲九九香蕉| 久久国产精品人妻蜜桃| 女同久久另类99精品国产91| www.999成人在线观看| 最新在线观看一区二区三区| 热re99久久精品国产66热6| 精品人妻熟女毛片av久久网站| 亚洲成a人片在线一区二区| 国产精品久久久久久精品古装| 大香蕉久久成人网| 国产亚洲av高清不卡| 午夜福利在线观看吧| 国产精品99久久99久久久不卡| 纵有疾风起免费观看全集完整版| av免费在线观看网站| 久久亚洲真实| 欧美成人午夜精品| 在线观看免费日韩欧美大片| 美女视频免费永久观看网站| 女警被强在线播放| 国产男靠女视频免费网站| 日韩一卡2卡3卡4卡2021年| 国产在线一区二区三区精| 亚洲国产av新网站| 丁香六月天网| 777米奇影视久久| 欧美在线黄色| 国产精品久久电影中文字幕 | 亚洲精品美女久久久久99蜜臀| 黄色a级毛片大全视频| 亚洲第一青青草原| 久久99热这里只频精品6学生| 国产在线视频一区二区| 久久国产亚洲av麻豆专区| 欧美日韩中文字幕国产精品一区二区三区 | 成人av一区二区三区在线看| 国产精品美女特级片免费视频播放器 | 国产精品成人在线| 久久久久久久大尺度免费视频| 免费人妻精品一区二区三区视频| 激情视频va一区二区三区| 香蕉国产在线看| 美女视频免费永久观看网站| 国产成人一区二区三区免费视频网站| 国产野战对白在线观看| 777米奇影视久久| h视频一区二区三区| svipshipincom国产片| 一进一出好大好爽视频| 黄色怎么调成土黄色| 日韩三级视频一区二区三区| 9191精品国产免费久久| 香蕉丝袜av| 欧美国产精品va在线观看不卡| 男女之事视频高清在线观看| 欧美人与性动交α欧美软件| 大香蕉久久网| 熟女少妇亚洲综合色aaa.| 精品国产亚洲在线| 精品国产一区二区三区久久久樱花| 啦啦啦在线免费观看视频4| 久久天堂一区二区三区四区| 国产欧美日韩综合在线一区二区| 欧美国产精品va在线观看不卡| 亚洲国产精品一区二区三区在线| 在线观看66精品国产| 桃红色精品国产亚洲av| 久久久久久久大尺度免费视频| 国产成人av教育| 男女午夜视频在线观看| 国产亚洲欧美精品永久| 另类亚洲欧美激情| 黄色a级毛片大全视频| 大香蕉久久网| 又黄又粗又硬又大视频| 亚洲国产欧美一区二区综合| 成人特级黄色片久久久久久久 | 在线观看66精品国产| 成人手机av| 国产高清视频在线播放一区| 夜夜夜夜夜久久久久| 日韩视频在线欧美| 欧美大码av| 亚洲精品美女久久av网站| 啦啦啦视频在线资源免费观看| 精品久久久久久久毛片微露脸| 中文字幕精品免费在线观看视频| 中亚洲国语对白在线视频| 日本黄色视频三级网站网址 | 国产成人精品久久二区二区免费| 免费女性裸体啪啪无遮挡网站| 亚洲一区中文字幕在线| 国产精品偷伦视频观看了| 亚洲国产成人一精品久久久| 99热网站在线观看| h视频一区二区三区| 91麻豆精品激情在线观看国产 | 可以免费在线观看a视频的电影网站| 男女无遮挡免费网站观看| 一级毛片电影观看| 久久久水蜜桃国产精品网| 精品少妇内射三级| 亚洲国产精品一区二区三区在线| 日韩一区二区三区影片| 午夜老司机福利片| 美女午夜性视频免费| 丰满人妻熟妇乱又伦精品不卡| 国产精品二区激情视频| 丝袜美足系列| 99国产精品一区二区蜜桃av | 99re6热这里在线精品视频| 国产免费视频播放在线视频| 久久精品国产亚洲av高清一级| 少妇 在线观看| 后天国语完整版免费观看| 日韩欧美国产一区二区入口| 亚洲精品国产一区二区精华液| a级片在线免费高清观看视频| 99精品在免费线老司机午夜| 免费观看av网站的网址| 亚洲午夜精品一区,二区,三区| 亚洲av日韩在线播放| 成人永久免费在线观看视频 | 天堂8中文在线网| 考比视频在线观看| 国产精品欧美亚洲77777| av在线播放免费不卡| 精品国产乱码久久久久久小说| 精品国产超薄肉色丝袜足j| 黄片大片在线免费观看| 亚洲av成人不卡在线观看播放网| 91麻豆av在线| 99精品欧美一区二区三区四区| 亚洲成人手机| 久久亚洲真实| 纯流量卡能插随身wifi吗| 久久精品国产99精品国产亚洲性色 | 天天操日日干夜夜撸| 动漫黄色视频在线观看| 两人在一起打扑克的视频| 精品人妻在线不人妻| 脱女人内裤的视频| 亚洲精品中文字幕一二三四区 | aaaaa片日本免费| h视频一区二区三区| 日本av手机在线免费观看| 欧美日韩亚洲综合一区二区三区_| av免费在线观看网站| av福利片在线| 日韩 欧美 亚洲 中文字幕| 亚洲情色 制服丝袜| 久久国产精品大桥未久av| 97人妻天天添夜夜摸| 久久香蕉激情| 日韩 欧美 亚洲 中文字幕| 精品一区二区三区av网在线观看 | 国产精品电影一区二区三区 | 国产精品免费大片| 国产有黄有色有爽视频| 女同久久另类99精品国产91| 亚洲国产av新网站| 国产精品久久久人人做人人爽| 一级毛片女人18水好多| 国产免费福利视频在线观看| 日韩中文字幕欧美一区二区| 夜夜夜夜夜久久久久| 久久久欧美国产精品| 久久国产亚洲av麻豆专区| 国产成人精品久久二区二区91| 国产精品久久久久久精品古装| 国产成人av教育| 久久亚洲精品不卡| 真人做人爱边吃奶动态| 国产精品 国内视频| 18禁观看日本| 亚洲精品国产一区二区精华液| 国产一区二区三区综合在线观看| 757午夜福利合集在线观看| 两性夫妻黄色片| 波多野结衣av一区二区av| 久久热在线av| 免费观看av网站的网址| 另类精品久久| 精品欧美一区二区三区在线| 黄片小视频在线播放| 99久久99久久久精品蜜桃| 亚洲精品自拍成人| 日韩制服丝袜自拍偷拍| 伦理电影免费视频| av有码第一页| 国产精品1区2区在线观看. | 亚洲成a人片在线一区二区| tube8黄色片| 成人国语在线视频| 亚洲国产成人一精品久久久| 欧美日韩视频精品一区| 大型黄色视频在线免费观看| 亚洲精品乱久久久久久| h视频一区二区三区| √禁漫天堂资源中文www| 啦啦啦免费观看视频1| 亚洲国产中文字幕在线视频| 一二三四社区在线视频社区8| 亚洲va日本ⅴa欧美va伊人久久| 男人操女人黄网站| 99re在线观看精品视频| 日日爽夜夜爽网站| 一级片免费观看大全| 国产深夜福利视频在线观看| 成人影院久久| 中文字幕另类日韩欧美亚洲嫩草| 国产精品久久久久久精品古装| 欧美成人免费av一区二区三区 | 亚洲七黄色美女视频| 少妇粗大呻吟视频| 亚洲欧洲日产国产| 老司机影院毛片| 一区二区三区激情视频| 精品久久蜜臀av无| 亚洲精品粉嫩美女一区| 国产精品免费视频内射| 操美女的视频在线观看| 深夜精品福利| 亚洲一区中文字幕在线| 精品国产一区二区久久| 欧美激情 高清一区二区三区| 中文字幕精品免费在线观看视频| 久9热在线精品视频| 精品一品国产午夜福利视频| 精品卡一卡二卡四卡免费| 嫁个100分男人电影在线观看| 国产成人系列免费观看| 人人妻人人添人人爽欧美一区卜| 99国产精品一区二区蜜桃av | 久久中文字幕人妻熟女| 蜜桃国产av成人99| 亚洲国产中文字幕在线视频| 久久国产精品大桥未久av| 国产亚洲一区二区精品| 成人三级做爰电影| 国产免费现黄频在线看| 建设人人有责人人尽责人人享有的| 老司机午夜福利在线观看视频 | 人人澡人人妻人| 在线看a的网站| 日韩制服丝袜自拍偷拍| 国产一区二区 视频在线| 亚洲av日韩在线播放| 韩国精品一区二区三区| 欧美久久黑人一区二区| 久久久久久久精品吃奶| 日韩欧美国产一区二区入口| 国产精品一区二区免费欧美| 纵有疾风起免费观看全集完整版| 人人妻,人人澡人人爽秒播| 黄片播放在线免费| 天天操日日干夜夜撸| 午夜免费成人在线视频| 黄色怎么调成土黄色| a级毛片在线看网站| 在线观看人妻少妇| 精品国产乱子伦一区二区三区| 国产精品 国内视频| 久久久国产欧美日韩av| 国产aⅴ精品一区二区三区波| 国产午夜精品久久久久久| 我要看黄色一级片免费的| 老鸭窝网址在线观看| 天堂俺去俺来也www色官网| 制服诱惑二区| 日韩制服丝袜自拍偷拍| 国产成人啪精品午夜网站| 视频区欧美日本亚洲|